Interferon therapy of acute hepatitis C in dialysis patients: Meta-analysis

Journal of Viral Hepatitis

Volumn 19, Issue 11, 2012, Pages 784-791

  Fabrizi, Fabrizio ^a,b   Dixit, V ^b   Messa, P ^a   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

acute Hepatitis C; dialysis; dropout; interferon; meta analysis; virological response

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT INTERFERON;

ABSENCE OF SIDE EFFECTS; ACUTE HEPATITIS; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FISTULA; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; LEUKOPENIA; META ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SIDE EFFECT; TREATMENT RESPONSE; VIRAL CLEARANCE; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84867403781     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01607.x     Document Type: Article

References (34)

1. Santantonio T, Wiegand J, Gerlach J,. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625-633.
2. Fabrizi F, Lunghi G, Ganeshan V, Martin P, Messa P,. Hepatitis C virus infection and the dialysis patient. Semin Dial 2007; 20: 416-422.
3. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y,. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 1998; 13: 62-67.
4. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Alijama P,. Natural history of acute HCV infection in haemodialysis patients. Clin Nephrol 2002; 58: 143-150.
5. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
6. Delwaide J, Bourgeois N, Gerard C, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20: 15-22.
7. Wiegand J, Buggisch P, Boecher W, et al. Early mono-therapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute HCV-II study. Hepatology 2006; 43: 250-256.
8. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-638.
9. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of peg-interferon alpha-2b mono-therapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329-333.
10. Poynard T, Conn HO,. The retrieval of randomised clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985; 6: 271-279.
11. Der Simonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
12. Petitti DB,. Approaches to heterogeneity in meta-analysis. Statist Med 2001; 20: 3625-3633.
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistencies in meta-analysis. Br Med J 2003; 327: 557-560.
14. Griveas I, Germanidis G, Visvardis G, et al. Acute hepatitis C in patients receiving haemodialysis. Ren Fail 2007; 29: 731-736.
15. Suleymanlar I, Sezer T, Isitan F, Yakupoglu G, Suleymanlar G,. Efficacy of interferon alpha in acute hepatitis C in patients on chronic haemodialysis. Nephron 1998; 79: 353-354.
16. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S,. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hep 2001; 8: 70-77.
17. Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnick A,. Treatment of early diagnosed HCV infection in haemodialysis patients with interferon-alpha. Blood Purif 2004; 22: 344-350.
18. Al-Harbi A, Malik G, Subaity Y, Mansy H, Abutaleb N,. Treatment of acute hepatitis C virus infection with alpha interferon in patients on haemodialysis. Saudi J Kidney Transpl 2005; 16: 293-297.
19. Engel M, Malta F, Gomes M, et al. Acute hepatitis C virus infection assessment among chronic haemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health 2007; 7: 50.
20. Rocha C, Perez R, Narciso J, et al. Interferon-alpha therapy within the first year after acute hepatitis C infection in haemodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol 2007; 19: 119-123.
21. Liu C, Liang C, Liu C, et al. Pegylated interferon alfa-2a mono-therapy for haemodialysis patients with acute hepatitis C. Clin Infect Dis 2010; 51: 541-549.
22. Ferreira A, Perez R, Ferraz M, et al. Acute hepatitis C in Brazil: results of a national survey. J Med Virology 2011; 83: 1738-1743.
23. Furusyo N, Hayashi J, Ariyama I, et al. Maintenance haemodialysis decreases serum hepatitis C virus RNA levels in haemodialysis patients with chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95: 490-496.
24. Hung K, Lee Y, Yen C, Wu K, Tsai T, Chen W,. Revised cut-off values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrol Dial Transplant 1997; 12: 180-183.
25. Fabrizi F, Ganeshan S, Lunghi G, Messa P, Martin P,. Antiviral therapy of hepatitis C in chronic kidney disease: meta-analysis of controlled clinical trials. J Viral Hep 2008; 15: 600-606.
26. Fabrizi F, Dixit V, Messa P, Martin P,. Interferon mono-therapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008; 15: 79-88.
27. Fabrizi F, Dixit V, Messa P, Martin P,. Pegylated interferon mono-therapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials. J Med Virol 2010; 82: 768-775.
28. Centers for Disease Control and Prevention. Surveillance for Acute Viral Hepatitis in United States, 2005. 56th edn. Atlanta, GA: Centers for Disease Control and Prevention; 2007, 1-24.
29. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 2008; 73 (Suppl. 109): S1-S99.
30. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alfa-2a vs standard interferon alfa-2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-530.
31. Rendina M, Castellaneta NM, Castellaneta A, et al. The treatment of chronic hepatitis C with peginterferon alpha2a (40 kDA) plus ribavirin in haemodialysis patients awaiting renal transplant. J Hepatol 2007; 46: 764-768.
32. Carriero D, Fabrizi F, Uriel A, Park J, Martin P, Dieterich DT,. Treatment of dialysis patients with chronic hepatitis C using pegylated-interferon and low dose ribavirin. Int J Artif Organs 2008; 31: 295-302.
33. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
34. Dienstag JL, McHutchison JG,. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-264.